Showing 3531-3540 of 5910 results for "".
- Sight Sciences Announces $30 Million Financinghttps://modernod.com/news/sight-sciences-announces-30-million-financing/2477405/Sight Sciences announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences’ OMN
- AAO Provides Updated COVID-19 Guidance for Outpatient Clinics and Elective Surgeryhttps://modernod.com/news/aao-provides-updated-guidance-for-outpatient-clinics-and-elective-surgery/2477395/In response to the state of national emergency declared at the federal level, particularly as COVID-19 progresses in a given community, ophthalmologists should seriously consider both the intensity of clinic scheduling and the issue of elective surgeries, particularly in elderly patients and thos
- The Vision Council Examines Consumers’ Attitudes About COVID-19 in a Survey for Its Membershttps://modernod.com/news/the-vision-council-examines-consumers-attitudes-about-covid-19-in-a-survey-for-its-members/2477382/The Vision Council released a new COVID-19 Optical Impact consumer survey. Conducted by The Vision Council’s research team in February, the study surveyed more than 10,000 adults across the U.S. and was designed to measure respondents’ level of concern over exposure to COVID-19, including measure
- Everads Therapy Enters Into Option Agreement to License Suprachoroidal Delivery System for Retinal Diseasehttps://modernod.com/news/everads-therapy-enters-into-option-agreement-to-license-suprachoroidal-delivery-system-for-retinal-disease/2477376/Everads Therapy announced that it has signed an option agreement with a large global pharmaceutical company, which will support the potential of its technology to overcome certain risks and side effects associated with current retinal disease treatment options, according to a company news release
- Retina Consultants of America Launches with Four Leading Partner Practiceshttps://modernod.com/news/retina-consultants-of-america-launches-with-four-leading-partner-practices/2477340/Retina Consultants of America (RCA), a physician management services organization recently formed by Webster Equity Partners, launched with four retina specialty practices. Practices include Retina Consultants of Houston, Retina Group of Florida, Long Island Vitreoretinal Consultants, and Retinal
- AbbVie-Allergan Deal Foes Try Again to Spur an FTC Crackdownhttps://modernod.com/news/abbvie-allergan-deal-foes-try-again-to-spur-an-ftc-crackdown/2477311/AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against
- Santen: VISIONARY Study Demonstrates Effectiveness of Tafluprost/Timolol Combination Therapy in Open-Angle Glaucomahttps://modernod.com/news/santen-visionary-study-demonstrates-effectiveness-and-tolerability-of-tafluprost-timolol-combination-therapy-in-open-angle-glaucoma/2477305/Santen has announced that the results of its real world evidence study, VISIONARY, have been published in Advances in Therapy. The study, which was conducted in 12 countries from across Europe with up to 6-mo
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery Systemhttps://modernod.com/news/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system/2477299/LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). “Recent research in our labs in both preclinical and clinical areas hav
- Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Deviceshttps://modernod.com/news/santen-and-verily-establish-joint-venture-to-develop-and-commercialize-unique-ophthalmic-devices/2477285/Santen Pharmaceutical and Alphabet subsidiary Verily announced the establishment of a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology. The new joint venture is driven by a mission to improve eye health for people everywhere, starting by
- Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DRhttps://modernod.com/news/regeneron-eylea-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-dr/2477283/Regeneron Pharmaceuticals announced positive 2-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection 2 mg (0.05 mL) in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The data were presented for the first time at the Angiogen